share_log

HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target

Benzinga ·  May 10 08:32

HC Wainwright & Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $30 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment